DRD2 and neuroleptic malignant syndrome: These agents exert antagonistic effects at dopamine D2 receptors in the central nervous system, leading to characteristic movement-related and autonomic side effects, commonly referred to as extrapyramidal symptoms (EPS), or in severe cases, life-threatening NMS.